Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2018
Event: The Company announced the approval of its new drug application by the United States Food and Drug Administration (FDA).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a regulatory event. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the regulatory approval of ONPATTRO™ (patisiran) lipid complex injection. This approval is for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the FDA approval. No specific financial guidance, future outlook, or risk factors are explicitly detailed within the body of this 8-K text, other than the successful regulatory milestone.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for commercial launch details and pricing strategy.
- Review the FDA approval letter for any specific restrictions or post-marketing requirements associated with ONPATTRO™.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial impact of this approval on revenue projections.
- Confirm the timeline for product availability and distribution following the August 10, 2018 approval.